For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    By product type
    Proteins and Peptides
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Products by research area:
  • Cancer
  • Cardiovascular
  • Cell Biology
  • Epigenetics & Nuclear Signaling
  • Developmental Biology
  • Immunology
  • Metabolism
  • Microbiology
  • Neuroscience
  • Signal Transduction
  • Stem Cells

Abcam acquires AxioMx to access new growth opportunities and extend antibody leadership

  • AxioMx provides a unique, cost-effective, and proprietary platform to produce recombinant monoclonal antibodies complementing Abcam's existing innovative production capabilities
  • This in vitro technology will enable Abcam to offer new tools to existing and new customers working in technically challenging areas such as infectious disease, toxins, nucleotides, and membrane bound proteins
  • AxioMx is already providing life science researchers, diagnostic companies, and drug discovery teams an efficient alternative to limitations they face with other systems

Cambridge, UK, 11 November 2015: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire the entire issued share capital of AxioMx, Inc. ("AxioMx") ("Acquisition") on a cash-free/debt-free basis for $20m upfront with further performance-based payments totalling $25m. These performance payments will be made over five years and are based upon successful completion of commercial and technical milestones. The consideration will be funded from a combination of Abcam's existing cash resources and newly issued shares.

 

AxioMx, which was founded in 2012 by Dr. Michael Weiner and Christopher McLeod, has 28 employees and is based in Branford, Connecticut, U.S. It has created a powerful and scalable in vitro recombinant monoclonal antibody technology which complements Abcam's existing antibody and immunoassay capabilities by targeting attractive and growing markets that traditional in vivo antibody production methods struggle to address. In addition to opening new markets, AxioMx's antibody and binder development capabilities mean that high quality antibodies can be produced within weeks, which is significantly faster than in vivo methods.

 

AxioMx currently provides access to its technology as a service to research institutes as well as diagnostics and therapeutics organisations. As part of the integration with Abcam, AxioMx will be re-focused to develop highly validated recombinant antibodies for inclusion in the Abcam catalogue, combining this technology with our renowned digital platform, brand and customer service capabilities.

 

The ability to produce highly validated antibodies is a key element of Abcam's strategy to increase the value of its products to the scientific community. After an initial period of investment and production scale up, AxioMx is expected to contribute both to revenue growth and profitability in the next few years.

 

The Acquisition is expected to close formally by the end of this month.

 

Alan Hirzel, CEO of Abcam, said: "The acquisition of AxioMx is in line with our strategy of acquiring businesses which enable Abcam to increase the supply of high quality products generated from our own innovation, and allows us to respond more quickly to our customers' needs. This acquisition enhances our ability to serve emerging life science needs and supports our mission to be the most influential and recommended company for life scientists worldwide. After an extensive review of alternate scaffold and other in vitro technologies, we are confident that AxioMx has created unique, high quality and economically attractive methods to serve customers in research, diagnostic and drug discovery labs globally. We look forward to working with AxioMx to scale up their production and enhance our product offering."

 

Christopher McLeod, President and CEO of AxioMx, commented: "Michael Weiner and I founded AxioMx with a vision to revolutionise proteomics by developing technologies to create recombinant antibodies in days. We have made great progress towards this goal, while also developing methods enabling us to generate antibodies against targets that can't be addressed with traditional in vivo technologies. We are excited that our team will be able to utilise their expertise in support of Abcam's mission and to serve its extensive global customer base."

 
Get resources and offers direct to your inbox Sign up
A-Z by research area
  • Cancer
  • Cardiovascular
  • Cell biology
  • Developmental biology
  • Epigenetics & Nuclear signaling
  • Immunology
  • Metabolism
  • Microbiology
  • Neuroscience
  • Signal transduction
  • Stem cells
A-Z by product type
  • Primary antibodies
  • Secondary antibodies
  • Biochemicals
  • Isotype controls
  • Flow cytometry multi-color selector
  • Kits
  • Loading controls
  • Lysates
  • Peptides
  • Proteins
  • Slides
  • Tags and cell markers
  • Tools & Reagents
Help & support
  • Support
  • Make an Inquiry
  • Protocols & troubleshooting
  • Placing an order
  • RabMAb products
  • Biochemical product FAQs
  • Training
  • Browse by Target
Company
  • Corporate site
  • Investor relations
  • Company news
  • Careers
  • About us
  • Blog
Events
  • Tradeshows
  • Conferences
International websites
  • abcam.cn
  • abcam.co.jp

Join with us

  • LinkedIn
  • facebook
  • Twitter
  • YouTube
  • Terms of sale
  • Website terms of use
  • Cookie policy
  • Privacy policy
  • Legal
  • Modern slavery statement
© 1998-2023 Abcam plc. All rights reserved.